Kieran Gallahue - 23 Feb 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Director
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
23 Feb 2024
Net transactions value
-$7,804
Form type
4
Filing time
26 Feb 2024, 17:52:21 UTC
Previous filing
25 May 2023
Next filing
09 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $260,107 +7,056 +191% $36.86 10,757 23 Feb 2024 Direct
transaction EW Common Stock Gift $0 -7,056 -66% $0.000000 3,701 23 Feb 2024 Direct
transaction EW Common Stock Gift $0 +7,056 +11% $0.000000 70,277 23 Feb 2024 By Trust
transaction EW Common Stock Sale $267,911 -3,058 -4.4% $87.61 67,219 23 Feb 2024 By Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Director Stock Option (Right to Acquire) Options Exercise $0 -7,056 -100% $0.000000* 0 23 Feb 2024 Common Stock 7,056 $36.86 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $87.5908 to $87.6210. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.